Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
E-pub ahead of print

Recurrent glioblastoma versus late posttreatment changes: diagnostic accuracy of O-(2-[18F]fluoroethyl)-L-tyrosine positron emission tomography (18F-FET PET)

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Sex-specific gene and pathway modeling of inherited glioma risk

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Genome-wide association analysis identifies a meningioma risk locus at 11p15.5

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. VEGF-C Sustains VEGFR2 Activation under Bevacizumab Therapy and Promotes Glioblastoma Maintenance

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. PET imaging in patients with meningioma-report of the RANO/PET Group

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Cardiac dysfunction in cirrhosis: a 2-yr longitudinal follow-up study using advanced cardiac imaging

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Kinetics of the soluble urokinase plasminogen activator receptor (suPAR) in cirrhosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Cell-free DNA in newly diagnosed patients with glioblastoma - a clinical prospective feasibility study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: Diagnostic accuracy in previous studies of O-(2-[18F]-fluoroethyl)-L-tyrosine (18F-FET) PET in patients with suspected recurrent glioma may be influenced by prolonged dynamic PET acquisitions, heterogeneous populations, different non-standard-of-care therapies, and PET scans performed at different time points post radiotherapy. We investigated the diagnostic accuracy of a 20-minute 18F-FET PET scan in MRI-suspected recurrent glioblastoma 6 months after standard radiotherapy and its ability to prognosticate overall survival (OS).

METHODS: In total, 146 glioblastoma patients with 168 18F-FET PET scans were reviewed retrospectively. Patients with MRI responses to bevacizumab or undergoing re-irradiation or immunotherapy after 18F-FET PET were excluded. Maximum and mean tumor-to-background ratios (TBRmax, TBRmean) and biological tumor volume (BTV) were recorded and verified by histopathology or clinical/radiological follow-up. Thresholds of 18F-FET parameters were determined by receiver operating characteristic (ROC) analysis. Prognostic factors were investigated in Cox proportional hazards models.

RESULTS: Surgery was performed after 104 18F-FET PET scans, while clinical/radiological surveillance was used following 64, identifying 152 glioblastoma recurrences and 16 posttreatment changes. ROC analysis yielded thresholds of 2.0 for TBRmax, 1.8 for TBRmean, and 0.55 cm3 for BTV in differentiating recurrent glioblastoma from posttreatment changes with the best performance of TBRmax (sensitivity 99%, specificity 94%; P < 0.0001) followed by BTV (sensitivity 98%, specificity 94%; P < 0.0001). Using these thresholds, 166 18F-FET PET scans were correctly classified. Increasing BTV was associated with shorter OS (P < 0.0001).

CONCLUSION: A 20-minute 18F-FET PET scan is a powerful tool to distinguish posttreatment changes from recurrent glioblastoma 6-month postradiotherapy, and predicts OS.

Original languageEnglish
JournalNeuro-Oncology
Pages (from-to)e-pub
ISSN1522-8517
DOIs
Publication statusE-pub ahead of print - 6 Sep 2019

ID: 58390266